Trend — Injection, donanemab-azbt, 2 mg (J0175) in Medicare, the United States

The full twelve-year services and payments series for this market — per-year values, with the FFS-enrollment denominator beside each.

The compound annual growth for J0175 in the United States — endpoints exclude the introduction year; an Exclude 2020–21 view drops the pandemic years too.